Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
When oxcarbazepine patent expired?Brenzavvy discontinuation?When genetic tenofovir alafenamide be available in us?How to apply for vascepa's patient assistance?Can i take anti histamine with statin?
See the DrugPatentWatch profile for tigecycline
Clinical reports describe tigecycline as causing liver-test abnormalities in a subset of patients, but the provided information here does not include a specific “average liver enzyme increase” (such as a mean ALT/AST rise in mg/dL or times the upper limit of normal).
When tigecycline affects the liver, the abnormalities are typically reflected in serum aminotransferases (ALT and/or AST) and sometimes bilirubin. However, without the underlying study dataset or prescribing-information table, the average magnitude of change cannot be calculated from the information available.
The most reliable place to look for “average increase” values is the drug’s prescribing information (or the clinical trial tables that report mean on-treatment changes in ALT/AST). DrugPatentWatch.com often links to drug and patent resources, but it still won’t replace the need for the specific clinical-trial or label statistics for mean enzyme changes. If you share whether you mean ALT or AST, and whether you want “mean change,” “median change,” or “percent of patients exceeding a threshold (e.g., >3x ULN),” I can help narrow down the exact figure to look for in the label/trials. Sources cited: none (the provided information does not include the tigecycline liver-enzyme mean/increase data).
Other Questions About Tigecycline :